HBV RNA level in patients with HBV-related hepatocellular carcinoma after long-term antiviral therapy with nucleos(t)ide analogues and its clinical significance

Jing LI; Yu CAO; Yongmei FENG; Yuanqiang GUO; Bei JIANG; Chunyan WANG

doi:10.3969/j.issn.1001-5256.2021.10.013

Volume 37 Issue 10

Oct. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(10): 2324-2326

PDF( 1874 KB)

HBV RNA level in patients with HBV-related hepatocellular carcinoma after long-term antiviral therapy with nucleos(t)ide analogues and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2021.10.013

1.
Graduate School of Tianjin Medical University, Tianjin 300192, China
2a.
Department of Research, Tianjin Second People's Hospital, Tianjin 300192, China
2b.
Department of Hepatology, Tianjin Second People's Hospital, Tianjin 300192, China
3.
School of Pharmacy, Nankai University, Tianjin 300192, China

Research funding:

Tianjin Youth Science Fund (18JCQNJCH800)

Received Date: 2021-02-28
Accepted Date: 2021-04-08
Published Date: 2021-10-20

Abstract

Abstract

Objective To investigate HBV RNA level in patients with HBV-related hepatocellular carcinoma after long-term antiviral therapy and its clinical significance. Methods A total of 60 patients with HBV-related hepatocellular carcinoma who were admitted to Tianjin Second People's Hospital from June 2019 to August 2020 were enrolled in this study. These patients received antiviral therapy with nucleos(t)ide analogues (NAs) for at least two years, and high-sensitivity HBV DNA detection showed a HBV RNA level of < 20 IU/mL at least twice at an interval of 3 months. Liver function, HBV serum markers, and HBV RNA level were measured for all patients. The Kruskal-Wallis H test was used for comparison between multiple groups, and the Wilcoxon rank-sum test was used for comparison between two groups; a Pearson correlation analysis was used to investigate the influencing factors for HBV RNA. Results Among the 60 patients with HBV-related hepatocellualr carcinoma who received long-term antiviral treatment, 9 (15%) tested positive for HBV RNA. According to the level of alpha-fetoprotein (AFP), the patients were divided into AFP positive group and AFP negative group, and there was no significant difference in HBV RNA level between the two groups [0(0-3.57) vs 0(0-2.00), Z=-1.474, P=0.141). According to Barcelona Clinic Liver Cancer (BCLC) stage, they were divided into BCLC stage A group and BCLC stage B+C+D group, and there was no significant difference in HBV RNA level between the two groups [0(0-2.0) vs 0(0-2.0), Z=-0.607, P=0.544]. According to HBeAg level, the patients were divided into HBeAg positive group and HBeAg negative group, and there was a significant difference in HBV RNA level between the two groups [2.99(0-4.80) vs 0(0-0.50), Z=-3.400, P=0.001]. According to the titer of HBsAg, they were divided into HBsAg≤100 IU/mL group, 100 IU/mL < HBsAg < 1500 IU/mL group, and HBsAg ≥1500 IU/mL group, and there was a significant difference in HBV RNA level between the three groups [0(0-0.0) vs 0(0-0.20) vs 2.00(0.0-4.54), H=-7.899, P=0.019]. A Pearson correlation analysis was performed for age, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, alkaline phosphatase, alpha-fetoprotein, HBsAg, and HBeAg, and the results showed that HBsAg level was correlated with HBV RNA quantification (r=0.292, P < 0.05). Conclusion In patients with HBV-related hepatocellualr carcinoma receiving long-term antiviral therapy with NAs, HBV RNA can still be detected after HBV DNA is lower than the lower limit of detection. HBsAg titer may be correlated with serum HBV RNA level.
- Carcinoma, Hepatocellular,
- Hepatitis B Virus,
- Antiviral Agents

FullText(HTML)

References(10)

References

[1]	KAO JH, HU TH, JIA J, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B[J]. Aliment Pharmacol Ther, 2020, 52(10): 1540-1550. DOI: 10.1111/apt.16097.
[2]	JUNG KS, PARK JY, CHON YE, et al. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients[J]. J Gastroenterol, 2016, 51(8): 830-839. DOI: 10.1007/s00535-015-1153-1.
[3]	WANG J, SHEN T, HUANG X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016, 65(4): 700-710. DOI: 10.1016/j.jhep.2016.05.029.
[4]	GIERSCH K, ALLWEISS L, VOLZ T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol, 2017, 66(2): 460-462. DOI: 10.1016/j.jhep.2016.09.028.
[5]	WANG J, SHENG Q, DING Y, et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient[J]. J Hepatol, 2018, 68(4): 847-849. DOI: 10.1016/j.jhep.2017.10.030.
[6]	HALGAND B, DESTERKE C, RIVIÈRE L, et al. Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: A nosological and prognostic determinant[J]. Hepatology, 2018, 67(1): 86-96. DOI: 10.1002/hep.29463.
[7]	Bureau of Medical AdministrationNational Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007. 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
[8]	LOPATIN U. Drugs in the pipeline for HBV[J]. Clin Liver Dis, 2019, 23(3): 535-555. DOI: 10.1016/j.cld.2019.04.006.
[9]	BUTI M, TSAI N, PETERSEN J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection[J]. Dig Dis Sci, 2015, 60(5): 1457-1464. DOI: 10.1007/s10620-014-3486-7.
[10]	LIU YY, LIANG XS. Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA[J]. World J Hepatol, 2018, 10(9): 603-611. DOI: 10.4254/wjh.v10.i9.603.

Relative Articles

[1]	Ruitao YANG, Rui YANG, Xun DENG, Senxiang ZENG, Xiaoyan YANG. Diagnosis and treatment principles of liver injury induced by antithyroid drugs[J]. Journal of Clinical Hepatology, 2024, 40(3): 621-625. doi: 10.12449/JCH240331
[2]	Guojing XING, Longlong LUO, Lifei WANG, Shunna WANG, Xiaofeng ZHENG, Lixia LU, Jiucong ZHANG. Role of mesenchymal stem cells and their exosomes in the treatment of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(3): 633-638. doi: 10.12449/JCH240333
[3]	Rui CHEN, Zhixin WANG, Haining FAN, Haijiu WANG. Research advances in the role of lymphocyte activation gene-3 in liver-related diseases[J]. Journal of Clinical Hepatology, 2021, 37(4): 977-981. doi: 10.3969/j.issn.1001-5256.2021.04.056
[4]	Hou JunXing, Yan FenQin, Yu YueCheng. The pathogenesis,diagnosis,and treatment of drug-induced liver injury with extrahepatic adverse drug reactions[J]. Journal of Clinical Hepatology, 2020, 36(3): 497-500. doi: 10.3969/j.issn.1001-5256.2020.03.003
[5]	Jing Jing, He TingTing, Wang RuiLin, Zhang Fan, Niu Ming, Guo YuMing, Zhu Yun, Xiao XiaoHe, Wang JiaBo. Detection of the risk signals of drug-induced liver injury: Challenges and advances[J]. Journal of Clinical Hepatology, 2020, 36(3): 491-496. doi: 10.3969/j.issn.1001-5256.2020.03.002
[6]	Huang Ang, Sun Ying, Zou ZhengSheng. Recent research advances in chronicity of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(3): 501-504. doi: 10.3969/j.issn.1001-5256.2020.03.004
[7]	Xiao XiaoHe. Combination of medicine and pharmacy assists for precise prevention and control of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(3): 489-490. doi: 10.3969/j.issn.1001-5256.2020.03.001
[8]	Yang Xue, Tu RongFang, Yang JinHui. Research advances in drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(3): 509-513. doi: 10.3969/j.issn.1001-5256.2020.03.006
[9]	Ye LiHong, Wang ChongKui, Shao Chen, Zhang HaiCong, Liu ZhiQuan, Wang TaiLing. Clinical and biochemical features of bile duct injury type of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(5): 1059-1064. doi: 10.3969/j.issn.1001-5256.2020.05.022
[10]	Liu Meng, Yang XuanZi, Yu LeCheng. Current status of the pathogenesis, diagnosis, and treatment of drug-induced cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(2): 252-257. doi: 10.3969/j.issn.1001-5256.2019.02.003
[11]	Han Ying, Chen Jie, Dan Jing, Liu YanMin, Zhang XiaoDan, Ren MeiXin, Du XiaoFei, Bian XinQu, Liu Dan, Huang YunLi, Huang ChunYang, Liao HuiYu. Value of fumarate hydratase antibody in differential diagnosis of autoimmune hepatitis and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2019, 35(6): 1326-1329. doi: 10.3969/j.issn.1001-5256.2019.06.029
[12]	Kong XiaoLu, Shao Xue, Li DongFu. Senile intestinal lymphangiectasia with drug-induced liver injury: A case report[J]. Journal of Clinical Hepatology, 2019, 35(8): 1800-1802. doi: 10.3969/j.issn.1001-5256.2019.08.030
[13]	Bian ZhaoLian, Shao JianGuo, Ma Xiong. Differential diagnosis of drug-induced liver injury and autoimmune hepatitis and related therapeutic strategies[J]. Journal of Clinical Hepatology, 2018, 34(6): 1156-1159. doi: 10.3969/j.issn.1001-5256.2018.06.003
[14]	Yu LeCheng, Fan Ye, Chen ChengWei. Diagnosis and treatment of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2018, 34(6): 1160-1165. doi: 10.3969/j.issn.1001-5256.2018.06.004
[15]	Chou LiXia, Fan ZuoPeng, Liu Ying, Liang Shan, Nie Wei, Lin Wei, Liu YiRong, Zhang Jing, Hu ZhongJie. Application of a modified diagnostic scale in diagnosis of acute drug-induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(7): 1328-1331. doi: 10.3969/j.issn.1001-5256.2017.07.025
[16]	Ji ChenHua, Zhang ZhuQing, Wang XiaoYuan, Lu ShuMing. Clinical features of elderly patients with drug-induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(3): 502-506. doi: 10.3969/j.issn.1001-5256.2017.03.021
[17]	Zhang Dong, Zhang Tao, Wu YuNan, Sun KeWei. A systematic analysis of the application of diagnostic criteria for drug-induced liver injury in China based on the literature[J]. Journal of Clinical Hepatology, 2017, 33(5): 919-923. doi: 10.3969/j.issn.1001-5256.2017.05.026
[18]	Yuan Ling, Yang YongGeng, Shen YouXiu, Ma YingCai. Research advances in drug- induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(2): 375-378. doi: 10.3969/j.issn.1001-5256.2017.02.038
[19]	Yu YueCheng, Fan Ye. Advances in Roussel Uclaf Causality Assessment Method for diagnosis of drug-induced liver injury and its comparison with structured expert opinion process[J]. Journal of Clinical Hepatology, 2016, 32(9): 1706-1713. doi: 10.3969/j.issn.1001-5256.2016.09.014
[20]	Lu Yi, Yu Hui. Discussion on idiosyncratic drug-induced liver injury in children[J]. Journal of Clinical Hepatology, 2015, 31(8): 1215-1217. doi: 10.3969/j.issn.1001-5256.2015.08.008

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (489) PDF downloads(52)

HBV RNA level in patients with HBV-related hepatocellular carcinoma after long-term antiviral therapy with nucleos(t)ide analogues and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2021.10.013

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

HBV RNA level in patients with HBV-related hepatocellular carcinoma after long-term antiviral therapy with nucleos(t)ide analogues and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2021.10.013

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content